New Generation Face Mask
Over 100,000 users worldwide
UK's No.1 official stockist
Aviro is a Reusable Swiss engineered virus killing mask, proven to neutralise COVID-19. ISO 18184 Anti-Viral Efficiency >99% (coronavirus)
AVIRO face masks are engineered with HeiQ Viroblock, a technology that inhibits the presence and growth of bacteria and viruses on the fabric. HeiQ Viroblock technology is proven to reduce 99.99% of human coronavirus SARS-CoV-2, the virus causing the COVID-19 pandemic.
Tracked 24 Delivery from London.
Comfortable for extended periods of time. The inner and outer layers made with industry leading filament grading technology. A lightweight, breathable and technical fabric that doesn’t retain moisture in the same way cotton and other natural fibres do.
Due to the self sanitizing nature of the anti-bacterial treatment on the fabric, AVIRO face masks need not be washed daily. We recommend washing after approximately 20 hours of use or if it gets visibly dirty
Advanced antimicrobial technology which reduces viral and bacterial activity. This diminishes the risk of transferring microorganisms to you and to other surfaces. Dermatologically tested and safe on skin.
request an email for back in stock notification.
HOW DOES IT WORK?
HeiQ Viroblock is added to fabric during the final stage of the manufacturing process. It uses a unique combination of silver and vesicle technologies in a dual defence against dangerous pathogens :
1. The HeiQ vesicle technology - many viruses are coated by a lipid (fatty) membrane that protects them. HeiQ vesicle technology targets the membrane surrounding the virus. This exposes the virus, deactivating and making it useless within minutes.
2. HeiQ silver technology - inhibits the replication of bacteria and deactivates viruses.
Swiss based company HeiQ is a leader in textile innovation, creating some of the most effective, durable and high-performing textile technology in the market today.
Textiles and clothing can provide a large surface for viruses and bacteria? These germs can remain active for days and be spread or transferred to other surfaces. HeiQ’s new technology HeiQ Viroblock is designed to inhibit the presence and growth of bacteria and enveloped viruses, such as coronavirus and influenza, on textile surfaces.
TESTING - AVIRO
Tested by Microbe Investigations AG (mis), AVIRO fabric treated with HeiQ Viroblock NPJ03 shows excellent antimicrobial activity with 99.69% reduction, and very good antimicrobial activity after x15 washes (99.29% reduction). AVIRO has also passed HeiQ’s qualitative antibacterial activity certification (hydrophilic fabrics). view doc
Aviro are committed to supplying safe and effective products to its consumers. To ensure the efficacy of the antiviral component they have completed their own independent ISO18184 antiviral testing and achieved a 99.29% against Influenza H1N1 ATCC VR-1683, Coronavirus (feline), Strain Munich. view doc
HeiQ Viroblock, has been thoroughly tested for safety, sustainability and its impact on the environment. Harmless to skin, HeiQ is best in class for their minimal use of active ingredients.
HeiQ Viroblock ingredients are compliant with INCI cosmetic grade, EU REACH compliant, US FIFRA compliant, ZDHC approved, Bluesign approved, OEKO-TEX® certified, EU BPR compliant, US EPA compliant.
The antiviral efficacy of HeiQ Viroblock has been proved with an extensive series of Good Laboratory Practice (GLP) Tests performed by accredited Microbiotest (a division of Microbac Laboratories) against a broad set of viruses.
HeiQ Viroblock is among the first textile technologies in the world to be proven effective against SARS-CoV-2 in the laboratory. SARS-CoV-2 is an enveloped virus that causes COVID-19. Tests have been conducted by HeiQ with the Peter Doherty Institute for Infection and Immunity in Melbourne, Australia showed that treated fabric achieved 99.99% reduction of the virus.
HeiQ Viroblock has also been tested against Influenza types H1N1, H5N1, H7N9, and Respiratory Syncytial Virus (RSV) and demonstrated significantly improved reduction of virus infectivity.